London-based semiconductor company MintNeuro, which builds specialised chips for neural devices ranging from implants to wearables, has announced a €4.4 million ($5 million) round to accelerate its product launch, expand delivery of pre-release silicon to partners, and grow its international presence.
The Round
The round was led by Odyssey Ventures, with participation from 33East, JSK Investments and Alumni Ventures. Returning investors Empirical Ventures, Jumpspace Ventures and early backers also took part.
Dorian Haci, co-founder and CEO of MintNeuro, said: “Every neural device depends on the chips inside it. Today, most device and therapy developers still have to choose between generic components that were never designed for the body and years of custom chip development. We are building the chips that end that trade-off. This funding moves us from technology validation to commercial scale-up, with more customer programmes, faster product launches and our chips in the hands of many more developers. Our ambition is clear: to make MintNeuro the semiconductor platform the global neurotechnology industry builds on.”
Michelle Robson, Founding Partner at Odyssey Ventures, added: “Neural devices such as BCIs represent one of the most exciting frontier technology opportunities today, and significant value will accrue to those solving the foundational infrastructure challenges that stand between innovation and widespread adoption. MintNeuro has the technology, market pull and ambition to become a globally important semiconductor company, and we are backing this exceptional team as it scales from the UK into global markets, including Silicon Valley.”
The Technology
Founded in 2022 as a spinout from Imperial College London, MintNeuro develops specialised chips that let devices connect with the brain and nervous system, helping innovators create new therapies for neurological and mental health conditions. The company says its chips give developers better performance than generic components, with less risk, lower cost and a faster route to market than custom chip design.
Progress across the industry has been held back by the lack of standard chips designed for the extreme power, size, safety and signal-quality demands of neural devices. MintNeuro’s answer is a modular semiconductor platform built for core functions such as neural sensing, signal processing and stimulation: listening to the body’s nerve signals, interpreting them, and delivering precise electrical pulses to treat disease or restore function.
Developers can build on these chips to create smaller, lower-power neural devices and move from research to clinical use sooner. The target applications span Parkinson’s disease, epilepsy, depression, hearing loss and inflammatory disease, across brain-computer interfaces (BCIs), neuromodulation systems, sensory prostheses and bioelectronic medicines.
Yiannis Eftychiou, co-founder and Partner at 33East, said: “What stood out to us is the sheer breadth of the hardware opportunity. MintNeuro is solving critical needs for neural implants today, with technology that can extend into wearables and beyond.”
Traction
MintNeuro has already delivered working silicon and reached key integration milestones with R&D partners, including Motif Neurotech and Amber Therapeutics. Earlier this year it announced a partnership and multi-year commercial chip supply agreement with Motif, supporting the development of Motif’s minimally invasive neurostimulator, initially targeting treatment-resistant depression.
Johnathan Matlock, co-founder and General Partner at Empirical Ventures, said: “We invested before the chips were in hand, and we are reinvesting now that MintNeuro has working silicon, deep customer traction and a clear path to becoming a category-defining semiconductor business.”
A Busy Year for European Neurotech
The round comes amid continued investment in European neurotechnology and neural-device infrastructure in 2026. EU-Startups has reported:
- €40.6 million for Eindhoven-based ONWARD Medical (spinal-cord stimulation)
- €20 million for Vienna’s nyra health (digital neurorehabilitation)
- €10 million for French-Belgian neuroClues (neurodiagnostics)
- €4.3 million for UK-based Cerca Magnetics (wearable brain imaging)
- €1.7 million for Zurich- and London-based Connectome
- €1.3 million for Amsterdam neuroprosthetics developer Phosphoenix
- €6 million Series A for Lausanne-based Xsensio (semiconductor-enabled health hardware)
Together, these 2026 rounds total approximately €83.9 million, or around €88.3 million including MintNeuro’s financing.
